-
- TRL (Technology readiness level) -
-
- Titre DELTA-CD20: New biomarker for diagnosis applications
- Description The EFS inventors established a novel CD20 alternative mRNA coding for truncated protein of 15-17 Kda (DELTA-CD20) lacking large parts of the transmembrane segments.
This protein is expressed at various levels in malignancies B-cells and is absent in normal B cells isolated from healthy donors. This data show that truncated protein CD20 could be used as a molecular marker for diagnosis, prognostic and monitoring B-cell malignant diseases.
Moreover the EFS inventors show that DELTA-CD20 expression is associated to RTX resistance. DELTA-CD20 protein is a potential target for treatment of B-cell lymphoproliferative disorders.
- Bénéfices This new truncated protein (Delta-CD20) could be used as Molecular diagnosis marker:
• Diagnosis of diseases related to B-Lymphocyte dysfunction.
• Measuring the development stage of pathological disease: The expression
level of DeltaCD20 is correlated with disease stage.
• Follow-up of the treatment Effectiveness.
- Nouveauté New spliced CD20 transcript and its use as molecular marker for diagnosis and monitoring B-cell malignant diseases.
This invention is patented.
- Mots clés CD20, Truncated protein CD20, biomarker, B-cell malignancies, diagnosis marker
- Secteurs Health
